DIANTHUS THERAPEUTICS INC.

NASDAQ: DNTH (Dianthus Therapeutics, Inc.)

Last update: 22 Oct, 3:05PM

78.53

0.43 (0.55%)

Previous Close 78.10
Open 77.13
Volume 1,093,922
Avg. Volume (3M) 828,032
Market Cap 4,392,526,336
Price / Sales 2.29
Price / Book 4.46
52 Weeks Range
32.22 (-58%) — 117.88 (50%)
Earnings Date 5 Nov 2026
Operating Margin (TTM) -2,852.71%
Diluted EPS (TTM) -2.83
Quarterly Revenue Growth (YOY) 33.10%
Total Debt/Equity (MRQ) 0.43%
Current Ratio (MRQ) 15.98
Operating Cash Flow (TTM) -90.87 M
Levered Free Cash Flow (TTM) -52.44 M
Return on Assets (TTM) -20.04%
Return on Equity (TTM) -28.73%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Dianthus Therapeutics, Inc. Mixed Bullish

AIStockmoo Score

-0.4
Analyst Consensus 0.0
Insider Activity NA
Price Volatility -2.4
Technical Moving Averages 2.5
Technical Oscillators -2.0
Relative Valuation NA
Financial Health 0.0
Macro Environment -0.3
AI Insight NA
AI Technical NA
Weighted Average -0.39

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
DNTH 4 B - - 4.46
APLM - - - -
SCTX - - - -
QNRX - - - 2.12
BCYC - - - 0.530
MDNAF - - - 23.76

Select this tab to load the latest available analysis.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 7.87%
% Held by Institutions 119.90%

No data within this time range.

No data within this time range.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria